Shots:
Senlang has granted Tempest an exclusive option to license its CD7-targeted lentiviral vector platform & in vivo CAR-T portfolio, incl. a BCMA/GPRC5D dual-targeting candidate for R/R MM & additional assets for hematologic malignancies & autoimmune diseases
Senlang’s platform uses targeted lentiviral vectors to deliver CAR transgenes to endogenous CD7+ T cells and NK cells,…
